176 related articles for article (PubMed ID: 22096023)
1. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM; Rischin D; Fisher R; Cao H; Kwok K; Truong D; McArthur GA; Young RJ; Giaccia A; Peters L; Le QT
Clin Cancer Res; 2012 Jan; 18(1):301-7. PubMed ID: 22096023
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.
Le QT; Fisher R; Oliner KS; Young RJ; Cao H; Kong C; Graves E; Hicks RJ; McArthur GA; Peters L; O'Sullivan B; Giaccia A; Rischin D
Clin Cancer Res; 2012 Mar; 18(6):1798-807. PubMed ID: 22383739
[TBL] [Abstract][Full Text] [Related]
3. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.
Rischin D; Young RJ; Fisher R; Fox SB; Le QT; Peters LJ; Solomon B; Choi J; O'Sullivan B; Kenny LM; McArthur GA
J Clin Oncol; 2010 Sep; 28(27):4142-8. PubMed ID: 20697079
[TBL] [Abstract][Full Text] [Related]
5. Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.
Polat B; Kaiser P; Wohlleben G; Gehrke T; Scherzad A; Scheich M; Malzahn U; Fischer T; Vordermark D; Flentje M
BMC Cancer; 2017 Jan; 17(1):6. PubMed ID: 28049456
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
7. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
[TBL] [Abstract][Full Text] [Related]
8. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Le QT; Taira A; Budenz S; Jo Dorie M; Goffinet DR; Fee WE; Goode R; Bloch D; Koong A; Martin Brown J; Pinto HA
Cancer; 2006 May; 106(9):1940-9. PubMed ID: 16532436
[TBL] [Abstract][Full Text] [Related]
9. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.
Le QT; Sutphin PD; Raychaudhuri S; Yu SC; Terris DJ; Lin HS; Lum B; Pinto HA; Koong AC; Giaccia AJ
Clin Cancer Res; 2003 Jan; 9(1):59-67. PubMed ID: 12538452
[TBL] [Abstract][Full Text] [Related]
10. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Mack PC; Redman MW; Chansky K; Williamson SK; Farneth NC; Lara PN; Franklin WA; Le QT; Crowley JJ; Gandara DR;
J Clin Oncol; 2008 Oct; 26(29):4771-6. PubMed ID: 18779603
[TBL] [Abstract][Full Text] [Related]
11. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.
Snitcovsky I; Leitão GM; Pasini FS; Brunialti KC; Mangone FR; Maistro S; de Castro G; Villar RC; Federico MH
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):807-11. PubMed ID: 19687403
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.
Zhang H; Ye QH; Ren N; Zhao L; Wang YF; Wu X; Sun HC; Wang L; Zhang BH; Liu YK; Tang ZY; Qin LX
J Cancer Res Clin Oncol; 2006 Nov; 132(11):709-17. PubMed ID: 16786357
[TBL] [Abstract][Full Text] [Related]
13. Plasma osteopontin is an independent prognostic marker for head and neck cancers.
Petrik D; Lavori PW; Cao H; Zhu Y; Wong P; Christofferson E; Kaplan MJ; Pinto HA; Sutphin P; Koong AC; Giaccia AJ; Le QT
J Clin Oncol; 2006 Nov; 24(33):5291-7. PubMed ID: 17114663
[TBL] [Abstract][Full Text] [Related]
14. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.
Peters LJ; O'Sullivan B; Giralt J; Fitzgerald TJ; Trotti A; Bernier J; Bourhis J; Yuen K; Fisher R; Rischin D
J Clin Oncol; 2010 Jun; 28(18):2996-3001. PubMed ID: 20479390
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.
DiSilvestro PA; Ali S; Craighead PS; Lucci JA; Lee YC; Cohn DE; Spirtos NM; Tewari KS; Muller C; Gajewski WH; Steinhoff MM; Monk BJ
J Clin Oncol; 2014 Feb; 32(5):458-64. PubMed ID: 24395863
[TBL] [Abstract][Full Text] [Related]
16. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen EE; Rosine D; Haraf DJ; Loh E; Shen L; Lusinchi A; Vokes EE; Bourhis J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):678-84. PubMed ID: 17293229
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
